Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Solid Tumors × olaparib × Clear all

Phase

Status

Active not recruiting 2 Terminated 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 15 Ovarian Neoplasms 13 Fallopian Tube Neoplasms 8 Triple Negative Breast Neoplasms 7 Pancreatic Neoplasms 7 Neoplasms 7 Neoplasm Metastasis 6 Prostatic Neoplasms 5 Endometrial Neoplasms 4 Neuroendocrine Tumors 3 Carcinoma, Ovarian Epithelial 3 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Lung Neoplasms 2 Glioma 2 Glioblastoma 2 Cholangiocarcinoma 2 Advanced Solid Tumor 2 Uveal Melanoma 1 Urogenital Neoplasms 1 Urinary Bladder Neoplasms 1 Solid Tumors 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 SCLC,Extensive Stage 1 Recurrent Ovarian High Grade Serous Adenocarcinoma 1 Recurrence 1 Prostatic Neoplasms, Castration-Resistant 1 Prostatic Diseases 1 Platinum-sensitive Ovarian Cancer 1

Interventions

Cetuximab 4 Injections 3 pembrolizumab 2 Bevacizumab 2 taxane 1 spartalizumab 1 ribociclib 1 pralsetinib 1 olaparib 1 ipatasertib 1 inavolisib 1 fludarabine phosphate 1 fludarabine 1 entrectinib 1 encorafenib 1 dapagliflozin 1 cemiplimab 1 binimetinib 1 atezolizumab 1 amivantamab 1 alectinib 1 Immunotherapy, Adoptive 1 IFL protocol 1 Folfox protocol 1 Cyclophosphamide 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07018622 2026-03-11

DAPA-ARMOR

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Phase 2 Recruiting

Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡